MDS-UPDRS subscale Part III ON medication in midpoints An insignificant improvement in the MDS-UPDRS Part III in the on-medication state was detected when pooling effects of GLP-1 receptor agonists vs
Rybelsus may interact with other medicines, but is not limited to: Angiotensin II Receptor Blockers (ARBs), such as candesartan or losartan, may increase the risk of low blood sugar
The benefits of beta-alanine are clear, but not all beta-alanine supplements are created equal
In a report earlier this year comparing semaglutide and tirzepatide for diabetics, the Institute for Clinical and Economic Review concluded that tirzepatide showed "greater reduction" in weight and other key markers, but "had a greater incidence of gastrointestinal side effects, severe adverse events, and discontinuation compared with semaglutide." Zepbound carries the risk of an array of potential side effects, the FDA says, including nausea, diarrhea, vomiting, constipation, and hair loss
Recent research has shown that people on GLP-1s lose up to 40% of their weight from lean mass not fat
